Incyte Corporation To Webcast A Discussion Of Its JAK Inhibitor, INCB18424, During The American Society of Hematology 49th Annual Meeting
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today that it will host a meeting to discuss clinical data on INCB18424, its lead janus-associated kinase (JAK) inhibitor, that is being presented at the upcoming American Society of Hematology 49th Annual Meeting. The webcast is scheduled to begin at 7:15 p.m. ET on Monday, December 10, 2007.